Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation.
BACKGROUND
We investigated the value of lung perfusion imaging in predicting the risk of developing pulmonary complications after chemoradiation (CRT) or radiation therapy (RT) for lung cancer.


METHODS
Fifty patients who underwent lung perfusion imaging before RT for lung cancer were included. Planar and single photon emission computed tomography/computed tomography images of the lungs were obtained. Lung perfusion score (LPS) was developed to visually grade localized perfusion defect per lung on a scale of 0 to 4 and perfusion pattern in the remaining lungs on a scale of 1 to 4. The LPS is the sum of the score for the localized perfusion defect in each lung plus the score for the remaining lungs perfusion. LPSs were correlated with pulmonary function tests and the patients were followed for 8 months after therapy to determine the incidence of grade 2 to 5 symptomatic therapy related pulmonary complications according to the common terminology criteria for adverse events (CTCAE 3.0).


RESULTS
Thirty-four patients underwent CRT and 16 underwent RT. The mean total radiation dose delivered was 56.1 +/- 10.4 Gy. Eighteen patients (36%) suffered from pulmonary complications at a mean interval of 3.4 months after therapy. Nine patients had grade 2, 7 had grade 3, 1 had grade 4, and 1 had grade 5 pulmonary complications. The mean LPS was 4.9 in patients who developed pulmonary complications versus 3.5 in patients who did not (p = 0.01). There were no significant difference between pulmonary function tests in the patients with pulmonary complications and the patient without. In addition, there were no significant differences between the mean lung radiation dose, the volume of lung irradiated or the percentage of lung receiving greater than 20 Gy between the two groups.


CONCLUSIONS
LPS using lung perfusion imaging is useful for predicting possible pulmonary complications after CRT or RT in lung cancer patients.
Gayed
Isis W
IW
Department of Nuclear Medicine, Sun Yat-sen University, China. igayed@di.mdacc.tmc.edu
Chang
Joe
J
Kim
E Edmund
EE
Nuñez
Rodolfo
R
Chasen
Beth
B
Liu
H Helen
HH
Kobayashi
Katsuhiro
K
Zhang
Yujing
Y
Liao
Zhongxing
Z
Gohar
Salman
S
Jeter
Melinda
M
Henderson
Louise
L
Erwin
William
W
Komaki
Ritsuko
R
D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D010477:Perfusion; D011379:Prognosis; D011446:Prospective Studies; D011832:Radiation Injuries / Q000000981:diagnostic imaging* / Q000209:etiology; D011879:Radiotherapy Dosage; D012307:Risk Factors; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome